Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
Amsterdam University Medical Centers · University of Amsterdam · +9 more institutions
Abstract
PURPOSE Preoperative chemoradiotherapy may improve the radical resection rate for resectable or borderline resectable pancreatic cancer, but the overall benefit is unproven. PATIENTS AND METHODS In this randomized phase III trial in 16 centers, patients with resectable or borderline resectable pancreatic cancer were randomly assigned to receive preoperative chemoradiotherapy, which consisted of 3 courses of gemcitabine, the second combined with 15 × 2.4 Gy radiotherapy, followed by surgery and 4 courses of adjuvant gemcitabine or to immediate surgery and 6 courses of adjuvant gemcitabine. The primary end point was overall survival by intention to treat. RESULTS Between April 2013 and July 2017, 246 eligible…
Citation impact
- FWCI
- 61.61
- Percentile
- 100%
- References
- 35
Authors
31- EVEva VersteijneCorresponding
Amsterdam University Medical Centers, University of Amsterdam
- MSMustafa Suker
Erasmus MC Cancer Institute
- KGKarin Groothuis
Netherlands Comprehensive Cancer Organisation
- JMJanine M. Akkermans-Vogelaar
Netherlands Comprehensive Cancer Organisation
- MGMarc G. Besselink
Amsterdam University Medical Centers, University of Amsterdam
Topics & keywords
- Medicine
- Gemcitabine
- Chemoradiotherapy
- Hazard ratio
- Surgery
- Randomized controlled trial
- Pancreatic cancer
- Survival rate
- Good health and well-being